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Abstract
X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder. Hemizygous males with
complete deficiency manifest neonatal acute hyperammonemia, while those with partial deficiency have a late presentation.
The symptomatology of heterozygotes depends on the inactivation pattern of X chromosome. Hyperammonemic episodes
can cause neurological damage and are potentially fatal. Here, we match clinical, biochemical, and molecular findings with
bioinformatics analyses to report genotype–phenotype correlations in 14 Argentine patients with OTCD from 11 unrelated
families: 4 hemizygotes with neonatal onset (complete OTC gene deletion, 533C > T, c.540þ1G > A, c.697delG); 4 hemizygotes
with late onset (c.216þ1G > A, c.386G > A, c.622G > A, c.829C > T); and 6 symptomatic heterozygotes (complete OTC gene
deletion, c.533C > T, c.452T > G, c.540þ1G > A, dupE1-9/delE10). Three of these mutations were previously unreported:
c.540þ1G > A, c.697delG, and dup1-9/del10. Our data highlight the relevance of combining molecular and bioinformatics analyses
for accurate diagnosis and outcome prediction in suspected patients with OTCD and the importance of carrier testing for
effective genetic counseling.
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Introduction
Ornithine transcarbamylase (OTC; EC 2.1.3.3) catalyzes the
formation of citrulline and inorganic phosphate from carbamyl
phosphate and ornithine in the urea cycle.1 The human OTC
gene is located on the short arm of the X chromosome (Xp11.4;
https://www.omim.org/entry/300461). The OTC enzyme is
expressed almost exclusively in the liver and intestinal mucosa,
but full activity of the urea cycle occurs only in the liver.
Ornithine transcarbamylase deficiency (OTCD;
MIM#311250), an X-linked disease, is the most frequent her-
editary defect of ureagenesis with an estimated incidence of
1:56 500 newborns per year in the United States.2 Hemizygotes
with complete OTCD present acute hyperammonemia in the
first week of life, while males with partial deficiency have a
late presentation, sometimes in adulthood.3 The severity of
OTCD symptoms in women depends mainly on the pattern of
X inactivation in the liver, and it ranges from asymptomatic to
almost as severe as in affected males.4
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In general, the clinical signs and symptoms are caused by
the toxic effects of hyperammonemia and glutamine in central
nervous system. Patients may present lethargy, vomiting, neu-
rological, and behavioral abnormalities and in the most severe
cases, cerebral edema, coma, and death. Biochemical abnorm-
alities include hyperammonemia, increased plasma glutamine
and decreased or absent citrulline, and increased urinary orotic
acid, although these last 2 findings are not always manifested
or detected. Carrier identification is very important as it allows
timely genetic counseling, thus minimizing the risk of poten-
tially fatal hyperammonemic crisis.5
Therapeutic approaches to urea cycle defects, including
OTCD, rely on ammonia scavengers (sodium benzoate and
sodium phenylbutyrate) in combination with nutritional ther-
apy (low-protein diet, arginine, or citrulline supplementation).
Meanwhile, hemodialysis or peritoneal dialysis is used in cases
of severe hyperammonemia (>500 μmol/L in neonates and
children; >200 μmol/L in adults). In some patients, liver trans-
plantation is also considered.6
To date, a total of 504 disease-causing mutations in the OTC
gene have been reported in the literature7 or registered in the
Human Gene Mutation Database (www.hgmd.org). Mutations
that block the enzyme’s catalytic action are invariably associ-
ated with acute neonatal hyperammonemia, while those that
allow residual activity may manifest over a wide age range,
from the neonatal period to late adulthood. Phenotypic hetero-
geneity is observed for mutations that preserve residual activity
of the enzyme, even among members of the same family; the
cause of this is still not well understood and seems to be due to
a combination of genetic factors and environmental variables
such as infections or other causes of catabolic stress. Bioinfor-
matic analysis of mutations using in silico strategies is used in
OTCD and other genetic diseases to predict severity.
In the current study, we matched clinical data with molecu-
lar, biochemical, and bioinformatic analyses to perform a gen-
otype–phenotype correlation analysis of OTC mutations found
in patients with OTCD from Argentina diagnosed at a single
center (CEMECO, Children’s Hospital of Co´rdoba).
Patients and Methods
We performed a descriptive, comparative, and correlational
study of patients diagnosed with OTCD in CEMECO, Chil-
dren’s Hospital of the Santı´sima Trinidad de Co´rdoba, between
1990 and 2017.
Biochemical analyses included determination of amino
acids8 and urinary orotic acid9 by high-performance liquid
chromatography and measurement of plasma ammonia by
spectrophotometry (Ammonium Kit, Randox Laboratories
LTD, United Kingdom).
The OTC gene mutations were identified using polymerase
chain reaction amplification, classical sequencing (Sanger),
and multiplex ligation-dependent probe amplification.10,11
Mutations were identified by comparison with the GenBank
reference sequence for human OTC (GenBank entries:
NG_008471.1, NP 000522.3, NM 000531.5, NC 000023.11).
Missense mutations were analyzed using different computa-
tional algorithms: CLUSTALW2 (http://www.clustal.org/
clustal2/), SIFT (http://blocks.fhcrc.org/sift/SIFT.html), Poly-
phen2(http://genetics.bwh.harvard.edu/pph/), PoPMuSiC
(http://babylone.ulb.ac.be/popmusic/), and SIFT Indel (http://
siftdna.org/www/SIFT_indels2.html).
The study was approved by the Institutional Committee on
Ethics of Research in Children and Adult Health. Informed
consent was obtained prior to collection of biological samples.
Results and Discussion
A total of 14 patients with OTCD belonging to 11 unrelated
families in Argentina were identified (Table 1). The phenotypic
distribution was 28.5% (4/14) hemizygotes with neonatal-onset
disease, 28.6% (4/14) hemizygotes with late-onset disease, and
42.8% (6/14) symptomatic heterozygous females. The age of
onset was between 48 hours and 10 years (mean: 29.9 months).
Clinical manifestations varied between cases, with patients
presenting 2 or more of the following signs and symptoms
either in the acute or in the chronic presentation: drowsiness,
lethargy, encephalopathy, convulsions, vomiting, behavior
alterations, irritability, developmental delay, recurrent dys-
function of the liver or cholestasis, and coma. Compared to
other population groups, our patients differed in their pheno-
typic distribution due to a greater number of symptomatic het-
erozygotes.7,12,13 Regarding disease progression, all 4 OTCD
males with the neonatal form died, while 3 of 4 males with late
onset survived. Neonatal forms were not diagnosed in sympto-
matic females. Among these, and due to the severity of the
hyperammonemic crises, 2 of 6 patients died and another one
fell into a vegetative state. Previous reports have shown a sur-
vival of 80% to 90% in symptomatic heterozygotes and a gen-
erally favorable prognosis.14-16 In those patients who survived
the hyperammonemic crisis, therapy consisted of low-protein
diet, treatment with ammonia scavengers, and essential amino
acid supplementation according to international recommenda-
tions and patient characteristics.
Biochemical findings (pooled data) for our patients with
OTCD at disease onset included mean plasma ammonia:
547 μmol/L (range: 70-1500 μmol/L, normal range: <50 μmol/
L), plasma glutamine: 800 μmol/L (range: 500-1300 μmol/L;
normal range: 450-750 μmol/L), citrulline, and arginine within
normal or decreased ranges and urinary orotic acid excretion in
13 of 14 cases.
Definitive diagnosis was obtained through genetic analysis,
which revealed 10 different OTC gene mutations in the patient
series, 3 of them previously unreported (Table 1). The identi-
fied mutations were uniquely found in each family, except for
patients 9 and 10, who shared the same mutation although there
was no known relationship between them.
The complete deletion of the OTC gene identified in family I
results in total loss of OTC protein function in the hemizygous
patient. The clinical presentation in the female carriers of this
family was, as expected, extremely variable, given the
X-linked inheritance of OTCD.4
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The novel mutation c.697delG (family IX) results in a
change in the reading frame, producing a premature stop codon
at amino acid 14, thereby truncating the protein in the position
245, near its carboxyl terminus. Bioinformatic analysis by
SIFT Indel (SIFT 4G Annotator version 2.3) suggests that the
transcript is therefore exposed to nonsense-mediated decay,
which makes this mutation equivalent to complete gene dele-
tion because the messenger RNA (mRNA) is not translated.
The program assigns a classification of 12 to this change, score
obtained according to several factors such as the fraction of
conserved bases of DNA, resulting amino acids, the maximum
relative indel location, and its distance to the union with the
exon, which predicts a highly harmful outcome (confidence of
0.858).17
The chromosomal rearrangement dup1-9/del10 described in
patient 14 has not been reported. It entails a duplication in
heterozygosis of the region between exons 1 and 9 plus a dele-
tion of the contiguous region that includes exon 10 until the end
of the gene, extending further into a region of the adjacent gene
TSPAN7, whose disruption is associated with X-linked mental
retardation. This alteration was demonstrated to be sponta-
neous. Even with specific treatment for OTCD, this girl had
frequent decompensations due to infectious processes and
developed a severe crisis that led to cerebral edema, cardior-
espiratory arrest, and death.
Five previously described single-base substitutions in the
OTC gene (c.386G>A; c.452T> G; c.533C>T; c.622G>A;
c.829C>T)18 were also found in our patients (Table 1). The
first is located on the last nucleotide of exon 4 and was classi-
fied initially as missense (p.Arg129His), although subsequent
studies revealed that it partially affected the splicing process19;
this mutation, identified in our study in a male with late disease
onset, had been reported in both males and symptomatic
females with severe or mild presentations. The other changes,
all missense mutations, were analyzed using 3 computational
algorithms (SIFT, Polyphen, and PoPMuSiC). Given the dif-
ficulty of assaying OTC enzymatic activity in patients, in
silico studies are considered the most feasible and reliable
way to analyze the severity of the mutations. After analyzing
all the in silico results (Table 2), the c.533C>T mutation can
be considered the most damaging of the series due to its strict
conservation in all the analyzed species and the scores
obtained in all the computational analyses. Moreover, it cor-
relates precisely with the clinical manifestation of our patient,
a seriously affected symptomatic carrier with a sibling that
died perinatally.
According to previous reports and our own experience,
mutations that completely abrogate the processing of OTC
mRNA or the protein’s catalytic activity usually manifest with
acute neonatal-onset hyperammonemia. That would be the case
of the novel splicing mutation c.540þ1G>A, to which we attri-
bute the severe neonatal form observed in patient 10 and his
siblings, who died at birth. Interestingly, the same mutation
was also identified in patient 9, a seemingly unrelated hetero-
zygous female with late disease onset. On the other hand,
patient 4 (a male with a late form) also has a splice-site muta-
tion (c.216þ1G>A) but in this case it affects the genesis and
processing of mature mRNA, in agreement with the original
description of this mutation.18 Individuals with sequence
variants that allow residual OTC activity may develop
hyperammonemia at any time in life, while others remain
asymptomatic. In patients with late-onset OTCD, acute hyper-
ammonemia can be triggered by factors such as fasting status,
infections, invasive medical procedures, or other environmental
Table 1. OTC Gene Mutations, Clinical Presentation, and Outcomes Identified in 14 Argentine Patients with OTCD.




Change Protein/Mutation Effect Clinical Outcome/Remarks
I 1 Female Late Yes – Complete deletion Decompensation during pregnancy
and death
I 2 Female Late Yes – Complete deletion Stable
I 3 Male Neonatal Yes – Complete deletion I 2 son, death in neonatal period
II 4 Male Late No c.216þ1G>A Splice site errors Stable
III 5 Male Late Yes c.386G>A p.Arg129His /splicing defects Stable
IV 6 Female Late Yes c.452T>G p.Leu151Arg Stable
V 7 Female Late Yes c.533C>T p.Thr178Met Persistent vegetative state
V 8 Male Neonatal Yes c.533C>T p.Thr178Met Death in neonatal period
VI 9 Female Late Yes c.540þ1G>Aa Splice site errors Stable
VII 10 Male Neonatal Yes c.540þ1G>Aa Splice site errors Death at 6 m, 2 brothers died in
neonatal period
VIII 11 Male Late – c.622G>A p.Ala208Thr Stable
IX 12 Male Neonatal Yes c.697delGa p.Leu232Leufs*14 Death in neonatal period
X 13 Male Late Yes c.829C>T p.Arg277Trp Death upon first disease crisis (10
years old)
XI 14 Female Late Yes – Exons 1-9 duplication; exon 10
deletiona,b
Death at 2 years old
aNovel mutation.
bDe novo mutation.
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triggers resulting in increased protein catabolism and ammonia
production.7
In conclusion, we discussed the clinical presentations, bio-
chemical findings, disease outcomes, and mutation spectrum of
a cohort of patients with OTCD from Argentina evaluated at a
single center. Genotype identification allowed exact diagnosis
and highlighted the importance of carrier testing for adequate
genetic counseling. Among the 10 genetic defects described in
our patient series, 3 are, to the best of our knowledge, novel and
had not been reported until now. The identified mutations were
validated with bioinformatic tools correlating genotype–pheno-
type, which allowed us to accurately predict, in most cases,
disease presentation and progression.
As the most common genetic defect within the spectrum of
urea cycle disorders, suspicion of OTCD, early confirmatory
diagnosis, and prompt initiation of treatment are essential to
avoid hyperammonemic crises that could cause irreversible
neurological damage and even death.
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1.95 1.34 Preserved in
11 species
Male, late onset
aPolymorphism Phenotyping: approach based on sequence and protein structure, assigns a score of 0 to benign variations, 0.5 for possibly damaging, and 1.0 for
damaging.
bSorting Intolerant from Tolerant: approach based on evolution, the result of the analysis is a binary classification of 1 “tolerated” and 0 “not tolerated”.
cPrediction of Protein Mutant Stability Changes: based on thermodynamic stability, characterized by free energy of folding DG, and the solubility of variants. AccSte %:
percentage of accessibility to the solvent of the mutated protein compared to the normal one; DDG: Relative folding free energy variation expressed in kcal/mol.
dAccording to amino acid sequence alignments using CLUSTALW2, the alignment for OTC gene was performed in 11 orthologous sequences.
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